Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 3

2(40.0%)

N/A

2(40.0%)

Phase 2

1(20.0%)

5Total

Phase 3(2)

N/A(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT07083765Phase 3Suspended

Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)

Role: lead

NCT03503773Phase 2Completed

The TARGET BP OFF-MED Trial

Role: lead

NCT02910414Phase 3Active Not Recruiting

TARGET BP I Clinical Trial

Role: lead

NCT02570113Not ApplicableCompleted

The Peregrine Post-Market Study for the Treatment of Hypertension

Role: lead

NCT02155790Not ApplicableCompleted

The Peregrine Study: A Safety and Performance Study of Renal Denervation

Role: lead

All 5 trials loaded